Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.
Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...
Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback